![]() |
|
|
Vol. 298, Issue 1, 219-225, July 2001
2-Adrenoceptors: Both Platelets and
Adipocytes Have
2A-Pharmacology
Department of Pharmacology, GlaxoSmithKline Pharmaceuticals, King
of Prussia, Pennsylvania
The recombinant
2-adrenoceptors, designated as
2a and
2d, have highly similar amino acid
sequences, but distinct pharmacological properties. It has been
suggested that these two receptor subtypes are species orthologs, since
the
2-adrenoceptors of a given species have
pharmacological characteristics corresponding to either the
2a- (human, pig) or
2d- (rat, mouse,
guinea pig, cow) adrenoceptor. Radioligand binding assays in rabbit
adipocyte suggest
2D-adrenoceptor pharmacology. However,
functional studies examining prejunctional
2-adrenoceptors in several tissues pharmacologically
define the receptor of the rabbit as an
2A-adrenoceptor
rather than an
2D-adrenoceptor. We characterized the
2-adrenoceptor of rabbit adipocyte and platelet, comparing the ability of norepinephrine and 13 adrenoceptor antagonists to inhibit the binding of [3H]RX821002 with the affinity
of these drugs for the human
2a-adrenoceptor or the rat
2d-adrenoceptor. Pharmacological characteristics of the
adipocyte and platelet receptor were very similar, with an excellent
correlation between pKi values
(r2 = 0.95, slope of regression = 1.01). Drug affinities for both platelet and adipocyte receptors
correlated better with the
2a-adrenoceptor (r2 = 0.68-0.77) than with the
2d-adrenoceptor (r2 = 0.37-0.38). Despite the relatively low affinity of the rabbit adipocyte
2-adrenoceptor for yohimbine and rauwolscine,
this receptor, as well as the platelet receptor, have
2A-adrenoceptor pharmacology. Subtle differences in the
2-adrenoceptor binding characteristics of these native
rabbit tissues compared with the recombinant human
2a-adrenoceptor may result either from minor differences
in the sequence of human and rabbit
2a-adrenoceptors or
from differences in the environment to which native and recombinant receptors are exposed.
This article has been cited by other articles:
![]() |
W. Ni, M. W. Li, K. Thakali, G. D. Fink, and S. W. Watts The Fenfluramine Metabolite (+)-Norfenfluramine Is Vasoactive J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 845 - 852. [Abstract] [Full Text] [PDF] |
||||